Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling, Fundamental & Clinical Pharmacology, vol.42, issue.6, pp.579-87, 2008. ,
DOI : 10.1111/j.1472-8206.2008.00648.x
Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.3, pp.299-319, 2001. ,
DOI : 10.1023/A:1011583210549
Facilitation of Drug Evaluation in Children by??Population Methods and Modelling???, Clinical Pharmacokinetics, vol.116, issue.4, pp.231-274, 2008. ,
DOI : 10.2165/00003088-200847040-00002
Optimal design in random-effects regression models, Biometrika, vol.84, issue.2, pp.429-471, 1997. ,
DOI : 10.1093/biomet/84.2.429
Fisher information matrix for nonlinear mixed effects multiple response models: Evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model, Statistics in Medicine, vol.60, issue.14, pp.1940-56, 2009. ,
DOI : 10.1111/j.0006-341X.2004.00148.x
URL : https://hal.archives-ouvertes.fr/inserm-00371363
Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics, Statistics in Medicine, vol.26, issue.6, pp.2623-2662, 2002. ,
DOI : 10.1002/sim.1041
A program for individual and population optimal design for univariate and multivariate response pharmacokinetic???pharmacodynamic models, Computer Methods and Programs in Biomedicine, vol.86, issue.1, pp.51-61, 2007. ,
DOI : 10.1016/j.cmpb.2007.01.004
Sparse-Sampling Optimal Designs in Pharmacokinetics and Toxicokinetics, Therapeutic Innovation & Regulatory Science, vol.29, issue.3, pp.997-1019, 1995. ,
DOI : 10.1177/009286159502900321
Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs, Computer Methods and Programs in Biomedicine, vol.65, issue.2, pp.141-51, 2001. ,
DOI : 10.1016/S0169-2607(00)00117-6
Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0, Computer Methods and Programs in Biomedicine, vol.98, issue.1, pp.55-65, 2010. ,
DOI : 10.1016/j.cmpb.2009.09.012
URL : https://hal.archives-ouvertes.fr/inserm-00431457
Population-based ADME Simulator, Expert Opinion on Drug Metabolism & Toxicology, vol.45, issue.2, pp.211-234, 2009. ,
DOI : 10.1080/00498250701620726
Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children, Clinical Pharmacokinetics, vol.45, issue.1, pp.931-56, 2006. ,
DOI : 10.2165/00003088-200645090-00005
Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice, Pediatric Anesthesia, vol.49, issue.3, pp.291-301, 2011. ,
DOI : 10.1111/j.1460-9592.2010.03323.x
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data, Nature Reviews Drug Discovery, vol.36, issue.2, pp.140-188, 2007. ,
DOI : 10.1038/nrd2173
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science, Annual Review of Pharmacology and Toxicology, vol.51, issue.1, pp.45-73, 2011. ,
DOI : 10.1146/annurev-pharmtox-010510-100540
Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review, Clinical Pharmacology & Therapeutics, vol.41, issue.2, pp.259-67, 2011. ,
DOI : 10.1046/j.0306-5251.2001.00031.x
The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review, Clinical Pharmacology & Therapeutics, vol.9, issue.3, pp.542-591, 2012. ,
DOI : 10.1038/clpt.2011.320
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science, Annual Review of Pharmacology and Toxicology, vol.51, issue.1, pp.6-12, 2002. ,
DOI : 10.1146/annurev-pharmtox-010510-100540
Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs, British Journal of Clinical Pharmacology, vol.37, issue.6, pp.691-704, 2006. ,
DOI : 10.1007/BF01065191
Development and Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Children, Clinical Pharmacokinetics, vol.42, issue.1, pp.1013-1047, 2006. ,
DOI : 10.2165/00003088-200645100-00005
Population-Based Analysis of Methadone Distribution and Metabolism Using an Age-Dependent Physiologically Based Pharmacokinetic Model, Journal of Pharmacokinetics and Pharmacodynamics, vol.4, issue.4, pp.485-518, 2006. ,
DOI : 10.1007/s10928-006-9018-0
Development of Optimal Kids Insulin Dosing System (KIDS) Formulas for Young Children with Type 1 Diabetes Mellitus (T1DM)., Diabetes Technol Ther, vol.14, pp.418-440, 2012. ,
DOI : 10.1210/endo-meetings.2010.PART3.P11.P3-512
Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4, Journal of Pharmacokinetics and Pharmacodynamics, vol.67, issue.1, pp.25-40, 2011. ,
DOI : 10.1007/s10928-010-9173-1
Population pharmacokinetics and optimal design of paediatric studies for famciclovir, British Journal of Clinical Pharmacology, vol.48, issue.4, pp.546-60, 2009. ,
DOI : 10.1111/j.1365-2125.2009.03479.x
Predictions of Metabolic Drug-Drug Interactions Using Physiologically Based Modelling, Clinical Pharmacokinetics, vol.283, issue.10, pp.239-58, 2010. ,
DOI : 10.2165/11318130-000000000-00000
Drug???drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.3, pp.635-59, 2008. ,
DOI : 10.1007/s10928-008-9104-6
URL : https://hal.archives-ouvertes.fr/inserm-00383725
Likelihood based approaches to handling data below the quantification limit using NONMEM VI, Journal of Pharmacokinetics and Pharmacodynamics, vol.34, issue.4, pp.401-422, 2008. ,
DOI : 10.1007/s10928-008-9094-4
Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model, Computational Statistics & Data Analysis, vol.51, issue.3, pp.1562-74, 2006. ,
DOI : 10.1016/j.csda.2006.05.007
URL : https://hal.archives-ouvertes.fr/inserm-00182360
Application of GEE procedures for sample size calculations in repeated measures experiments, Statistics in Medicine, vol.17, issue.14, pp.1643-58, 1998. ,
DOI : 10.1002/(SICI)1097-0258(19980730)17:14<1643::AID-SIM869>3.0.CO;2-3
Sample Size Calculations Based on Generalized Estimating Equations for Population Pharmacokinetic Experiments, Journal of Biopharmaceutical Statistics, vol.16, issue.2, pp.135-50, 2006. ,
DOI : 10.1002/sim.4780111406
Physiologically Based Pharmacokinetic Modeling 1: Predicting the Tissue Distribution of Moderate-to-Strong Bases, Journal of Pharmaceutical Sciences, vol.94, issue.6, pp.1259-76, 2005. ,
DOI : 10.1002/jps.20322
Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice, Pediatric Anesthesia, vol.49, issue.3, pp.291-301, 2011. ,
DOI : 10.1111/j.1460-9592.2010.03323.x
NONMEM users guide University of California, 1992. ,
Derivation of various NONMEM estimation methods, Journal of Pharmacokinetics and Pharmacodynamics, vol.80, issue.5, pp.575-93, 2007. ,
DOI : 10.1007/s10928-007-9060-6
Comparison of Model-Based Tests and Selection Strategies to Detect Genetic Polymorphisms Influencing Pharmacokinetic Parameters, Journal of Biopharmaceutical Statistics, vol.5, issue.6, pp.1084-1102, 2008. ,
DOI : 10.1111/j.1525-1438.2006.00593.x
URL : https://hal.archives-ouvertes.fr/inserm-00339183
Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of Gliclazide, Pharmaceutical Research, vol.91, issue.9, pp.2036-2085, 2006. ,
DOI : 10.1007/s11095-006-9067-5
URL : https://hal.archives-ouvertes.fr/inserm-00189557
Design in nonlinear mixed effects models: Optimization using the Fedorov???Wynn algorithm and power of the Wald test for binary covariates, Statistics in Medicine, vol.39, issue.28, pp.5162-79, 2007. ,
DOI : 10.1002/sim.2910
URL : https://hal.archives-ouvertes.fr/hal-00263513
Design evaluation in nonlinear mixed effect models: influence of covariance between random effects [abstract no. 2158], Population Approach Group in EuropePAGE, vol.7, issue.10, pp.page-meeting, 2011. ,
Influence of covariance between random effects in design for nonlinear mixed effect models with an illustration in paediatric pharmacokinetics, J Biopharm Stat ,